Clinical practice guideline demonstrates evidence-based strategies for migraine preventive therapy in adults, highlighting tailored care for comorbid conditions.
Key Points
To update evidence-based clinical recommendations on the initiation, selection, and management of pharmacologic prevention for adults with migraine.
A multidisciplinary panel performed a systematic review of studies published through June 6, 2024.
Recommendations were developed following the 2017 American Academy of Neurology Clinical Practice Guideline Process Manual, incorporating structured rationales and principles of care.
Guideline establishes clinical criteria for determining when to initiate pharmacologic preventive therapy and guidance on initial drug selection.
Recommendations outline medication selection tailored to specific populations, including individuals with hypertension, obesity, fibromyalgia, older age, pregnancy, lactation, or medication overuse.
Framework defines protocols for monitoring therapeutic efficacy, tracking adverse events, and systematically discontinuing preventive regimens.